Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPH is a non-specific abbreviation used in clinical and scientific literature to refer to several distinct substances. Most commonly in a pharmaceutical context, it refers to **cyproheptadine**, a first-generation antihistamine and serotonin antagonist used for allergic conditions, appetite stimulation, and the management of serotonin syndrome; it is also being investigated for motor recovery in chronic spinal cord injury. Additionally, CPH refers to **chicken protein hydrolysate**, a dietary supplement composed of bioactive peptides studied for its potential to reduce abdominal obesity and improve metabolic health. In agricultural and oncological research, CPH denotes **cocoa pod husk**, a natural extract rich in polyphenols being evaluated for anticancer activity against hepatocellular carcinoma. Finally, CPHs is a frequent shorthand for the **cephalosporin** class of beta-lactam antibiotics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CPH.